02544nas a2200301   4500000000100000008004100001260001600042653002400058653001700082653001700099653001500116653002500131653002400156653001800180653000900198100002000207700001800227700001600245700002500261700001800286700002100304700002600325245012600351856015300477300000900630520158900639022001402228       2023                            d  bElsevier BV10aInfectious Diseases10aParasitology10aEpidemiology10aIvermectin10aAntiparasitic Agents10aScientific Evidence10aHelminthiasis10aPeru1 aFailoc-Rojas VE1 aSilva-Díaz H1 aMaguiña JL1 aRodriguez-Morales AJ1 aDíaz-Velez C1 aApolaya-Segura M1 aValladares-Garrido MJ00aEvidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru  uhttps://www.sciencedirect.com/science/article/pii/S2405673123000375/pdfft?md5=b1068d30c145dc076f3906411b0876db&pid=1-s2.0-S2405673123000375-main.pdf  a1-313 a<p>Ivermectin has emerged as a therapeutic option for various parasitic diseases, including strongyloidiasis, scabies, lice infestations, gnathostomiasis, and myiasis. This study comprehensively reviews the evidence-based indications for ivermectin in treating parasitic diseases, considering the unique context and challenges in Peru. Fourteen studies were selected from a systematic search of scientific evidence on ivermectin in PubMed, from 2010 to July 2022. The optimal dosage of ivermectin for treating onchocerciasis, strongyloidiasis, and enterobiasis ranges from 150 to 200 μg/kg, while lymphatic filariasis requires a higher dose of 400 μg/kg (Brown et al., 2000). However, increased dosages have been associated with a higher incidence of ocular adverse events. Scientific evidence shows that ivermectin can be safely and effectively administered to children weighing less than 15 kg. Systematic reviews and meta-analyses provide strong support for the efficacy and safety of ivermectin in combating parasitic infections. Ivermectin has proven to be an effective treatment for various parasitic diseases, including intestinal parasites, ectoparasites, filariasis, and onchocerciasis. Dosages ranging from 200 μg/kg to 400 μg/kg are generally safe, with adjustments made according to the specific pathology, patient age, and weight/height. Given Peru's prevailing social and environmental conditions, the high burden of intestinal parasites and ectoparasites in the country underscores the importance of ivermectin in addressing these health challenges.</p>
  a2405-6731